Cell Cycle Changes in the Adenylate Cyclase of C6 Glioma Cells

RANDALL F. HOWARD and J. R. SHEPPARD
Dight Institute for Human Genetics, University of Minnesota, Minneapolis, Minnesota 55455. Dr. Howard’s present address is the Pharmakologisches Institut der Justus Liebig Universität, 6300 Giessen, Federal Republic of Germany

ABSTRACT The adenylate cyclase of C6 glioma cell cultures was characterized for sensitivity to the β-adrenergic agonist isoproterenol, as well as fluoride, and GTP as a function of the cell cycle. The mitotic phase of the cell cycle was emphasized because both the basal cellular cyclic AMP level and the intact C6 cell’s capacity to accumulate cyclic AMP in response to isoproterenol decreased during mitosis. Basal and stimulated adenylate cyclase activities in mitotic cells were decreased relative to the enzyme activities in the G1, S, and G2 phases of the cell cycle. Analysis of the β-adrenergic receptor using the radioligand (-)[3H]dihydroalprenolol showed that neither ligand affinity nor receptor density changed during the cell cycle, indicating that the reduced adenylate cyclase activity of the mitotic C6 cell was not caused by alterations in this hormone receptor. The reduction in the mitotic cell’s basal adenylate cyclase activity was more prominent than the decrease in isoproterenol-, fluoride, or GTP-stimulated activities, suggesting that the effectiveness of these enzyme activators (i.e., the efficiency of the coupling mechanism) was not attenuated during mitosis. These studies indicate that the intrinsic catalytic capacity (not the β-adrenergic receptor or the coupling mechanism) of the C6 adenylate cyclase complex is reduced during mitosis and contributes to the mitotic cell’s inability to accumulate and maintain the cyclic AMP concentration at the interphase level.

Intracellular levels of cyclic AMP decrease as cells enter mitosis and then rapidly increase as cells complete mitosis and enter the G1 phase of the cell cycle (5, 26, 39, 44, 45). To correlate the observed changes in intracellular cyclic AMP levels with cyclic AMP synthesis and hydrolysis, we examined adenylate cyclase (EC 4.6.1.1.) and phosphodiesterase (EC 3.1.4.17.) enzyme activities in synchronized cells. Sodium fluoride or hormone-stimulated adenylate cyclase activity generally was observed to be lower in enzyme preparations from mitotic cells than in those from cells within other phases (G1, S, G2) of the division cycle (14, 26, 28). However, basal adenylate cyclase activity increased linearly as cells progressed from early G1 to the next mitosis (14, 28). Cyclic AMP phosphodiesterase activity was found to increase during mitosis coincident with a decline in adenylate cyclase activity (26). An efflux of cyclic AMP during mitosis has also been observed (44).

These previous studies did not correlate cell cycle-specific alterations in the adenylate cyclase activity with changes in the intact cell’s capacity to accumulate cyclic AMP. In the most complete study reported, both basal and hormone-elevated levels of cellular cyclic AMP were assayed during the cell cycle using synchronized Cloudman melanoma cells (42). These studies demonstrated that an increased density of melanocyte-stimulating hormone (MSH) receptors in G2 was associated with a G2 phase-specific sensitivity to MSH (41, 42). However, because adenylate cyclase enzyme activity was not measured, a correlation could not be made between the cellular cyclic AMP level and the enzyme activity. Thus, a thorough examination and comparison of the cell cycle phase-dependent changes in cyclic AMP levels, adenylate cyclase specific activities, and hormone receptor characteristics has yet to be performed on a single experimental system.
We chose the C6 glioma cell line for this particular study because it is responsive to physiological concentrations of β-adrenergic agonists such as isoproterenol (13). Membranes prepared from these cells possess both a β-adrenergic-sensitive adenylate cyclase activity (4, 13, 20) and measurable β-adrenergic receptor-binding sites for the radiolabeled antagonist (−)[3H]dihydroalprenolol ([3H]DHA) (20, 21). The C6 cell line seemed especially suited as a model for assaying these activities during the cell cycle because of its apparent tight "coupling" between occupancy of the β-adrenergic receptor site by an agonist molecule and the subsequent activation of the adenylate cyclase moiety (21). We chose to focus on the interval of the cell cycle immediately before and after mitosis because of the suggested importance of cyclic AMP during mitotic events (5, 39).

In this communication we present evidence that both the basal cyclic AMP levels and the accumulation of cyclic AMP in response to the β-adrenergic agonist isoproterenol are depressed in mitotic C6 cells relative to cells synthesizing DNA, cells in G2, or cells in early G1. Furthermore, both basal and stimulated adenylate cyclase-specific activities, but neither [3H]DHA binding site affinity nor density, decrease coincident with intact cell changes in mitosis. Surprisingly, there was an increase in the mitotic cell's stimulation index, which is calculated by dividing the effector-augmented adenylate cyclase activity by the basal enzyme activity.

MATERIALS AND METHODS

Cell Culture

Cultures of C6 cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 2 mM L-glutamine and 10% fetal calf serum (the growth medium) in the absence of antibiotics. The fetal calf serum was incubated before use for 18 h at 37°C to hydrolyze serum cyclic AMP and then heat treated at 56°C for 30 min to inactivate complement and phosphodiesterase activities. Cells were maintained at 37°C in a 10% CO2-90%, air, humidified atmosphere. Cell cultures were judged free of mycoplasma contamination by both measurement of [H]Hurdine/[H]Uracil incorporation (35) and scanning electron microscopy.

Broken Cell Preparations

The growth medium was removed and the culture plates were rinsed twice with 10 ml of ice-cold Dulbecco's phosphate-buffered saline without Ca2+ or Mg2+ (PBS-CMF) and drained well. Subsequent steps were performed at 4°C. The cells were quickly rinsed with 5 ml of 50 mM Tris-HCl, pH 7.4, at 4°C, and the cells scraped from the plates into a chilled tube in 10 ml of Tris-HCl, pH 8.0, at 4°C and allowed to swell for 10 min. The enlarged cells were homogenized in a tight-fitting 10-ml glass-Teflon Potter Elvehjem-type tissue grinder by five slow strokes. After at least 90% of the cells were ruptured, the homogenate was used immediately for the determination of adenylate cyclase activity.

Membranes from C6 cells were used to characterize the β-adrenoceptor binding sites prepared by homogenization of 1 mM Mg2+·. The intact cells and nuclei then were removed by centrifugation for 5 min at 1,200 rpm in a Sorvall HL-4 rotor (DuPont Instruments-Sorvall, DuPont Co., Newtown, Conn.) (max = 200 g). The supernate was then centrifuged in a Sorvall SS 34 rotor (max = 30,000 g) for 20 min. The pellet was rinsed with 1 ml of 10 mM Tris-HCl and resuspended in a suitable volume of 10 mM Tris-HCl with two strokes of the homogenizer.

Adenylate Cyclase Assay

The final concentration of the components used in the standard adenylate cyclase reaction mixture were: 80 mM Tris-maleate, pH 8.3, at 30°C, 1 mM ATP, 10 mM MgCl2, 1 mM theophylline, and a nucleotide-regenerating system consisting of 40 μg (24 U) of pyruvate kinase, 2.5 mM phosphoenolpyruvate, and 3 mM KCl, in a final volume of 50 μl. Test agents, when used, were included in this reaction volume. The reaction was initiated by the addition of 50 μl of enzyme preparation to the assay tubes, which had been preequilibrated to 30°C for at least three min in a shaking water bath. After incubation for exactly 10 min, the reaction was terminated in a boiling water bath for 3 min. The tube was then placed in an ice-water bath. Experimental blanks were boiled upon lyophilization without prior incubation to assess the effect of additives on the cyclic AMP-binding assay and to detect any endogenous cyclic AMP. All the boiled samples were centrifuged at 1,000 × g for 20 min before aliquots of the supernate were assayed, with or without dilution, for cyclic AMP content.

Cyclic AMP Analysis

This was modified from the method of Brown et al. (3). Protein kinase was prepared from bovine adrenal glands and was purified using the procedure described in reference 3. Cyclic AMP values were obtained by the linear regression analysis of standard curves constructed from the log of the bound [3H]cyclic AMP (cpm) as a function of the log of the total picomoles of unlabeled cyclic AMP. The coefficient of variation of this competitive binding assay was ±4%. Incubation of a sample with cyclic nucleotide phosphodiesterase eliminated 90-100% of the competition between an unknown and [3H]cyclic AMP for the binding protein.

Cyclic AMP Content of Intact Cells

Intact cell experiments were conducted in a 37°C warm room. Cells on 35-, 60-, or 100-mm culture plates were kept in a 37°C cell culture incubator until they were used. Culture medium was removed with a vacuum pump-aspirator assembly and the cells were quickly rinsed with two 1.8-ml volumes of Dulbecco's phosphate-buffered saline supplemented with Ca2+ and Mg2+ (PBS-CM). The basal cyclic AMP level was determined after the addition of 1.0 ml of 5% TCA at 4°C. Alternatively, to examine the effects of β-adrenergic agonists on intracellular cyclic AMP levels, we added PBS-CM with the phosphodiesterase inhibitor Ro 20-1724 to cover the cells (1.8 ml). Within 30 s the incubation with or without β-adrenergic agonist and/or antagonist was begun. After an appropriate incubation time the buffer was removed and 1.0 ml of cold 5% TCA was added to extract the cyclic AMP. The plates were then kept at 4°C for ~30 min. TCA was removed from the cell extract by ether extraction. Cyclic AMP was measured as described above.

(−) [3H]DHA Binding to Membrane Preparations

The assay of the [3H]DHA specific binding sites of C6 cells utilized a reaction mixture identical to that of the adenylate cyclase assay. The reaction was initiated by the addition of the membrane protein (30–100 μg of protein) to the otherwise complete mixture (in polystyrene tubes), giving a final volume of 100 μl. The binding was allowed to proceed for 13–18 min at 30°C in a shaking water bath. To end the binding reaction, the contents of the tube were diluted with 1 ml of ice-cold 50 mM Tris-Cl, pH 8 at 0°C (buffer A) and rapidly poured over a glass fiber GF/C filter held in a Millipore rapid-sampling vacuum manifold (Millipore Corp., Bedford, Mass.). The tube was then washed with another 4 ml of buffer A. After the filtration of all the incubation tubes, the vacuum was increased to remove trapped water containing [3H]DHA. The filters were then placed in scintillation vials and mixed in toluene-based scintillation cocktail (90% toluene, 10% vol/vol Biosolv BBS-3, and 0.4% vol/vol 2,5-diphenyloxazole). The receptor-bound [3H]DHA was determined in a Beckman scintillation counter (35% efficiency) after the filters had clarified (~2 h later). Under these conditions the steady-state association of 10 nM [3H]DHA was attained within 1 min and remained constant for at least 20 min. Binding was proportional to the membrane concentration, was saturable, and could be reversed by the addition of unlabelled alprenolol or propranolol. Specific binding was defined as the difference in [3H]DHA bound in the presence and absence of 10−4M (−) alprenolol (unlabeled), each performed in triplicate. Non-specific binding (that [3H]DHA bound in the presence of unlabeled (−) alprenolol) was independent of incubation time and dependent on [3H]DHA concentration. Scatchard analysis (31) of specific binding data was utilized to determine the binding capacity and Kd (dissociation constant) of [3H]DHA of cell lysates.

Cell Synchronization

Flasks of stock cells were trypsinized and diluted in the proper volume of medium such that there were 20–30 × 104 cells/cm2 of surface area and, 24 h later, the first of two thymidine blockades commenced.
Cells were exposed to 0.1 mM thymidine in growth medium for 17 h, washed free of thymidine, and incubated for 11 h, incubated in 1 mM thymidine for an additional 13 h, and again rinsed free of thymidine. Such exposure to 1 mM thymidine had no effect on the ability of the Cs cells to population to resume proliferation (detected by the incorporation of [3H]thymidine during a 20-h labeling period) compared to unsynchronized cultures; the labeling indices were 91 and 94%, respectively. After the release from the second thymidine block, cells were allowed to progress into S phase for 4 h. Sterile colcemid (in growth medium) was added to give a final concentration of 0.05 μg/ml (0.13 μM). The incubation was continued for 6 h, allowing an accumulation of up to 70% of the cells in mitosis (late prophase). The colcemid blockade was ended by rinsing the cells two times with DMEM and adding complete growth medium. 1 h later the medium was replaced with fresh growth medium. Less than 5% of the cells remained in mitosis after 1 h in colcemid-free medium.

The mitotic index (MI; cells in late prophase to early telophase) was determined in 0.1% acetic acid-75% ethanol fixed cells by counting 400-600 cells using a phase microscope fitted with an ocular grid. The number of cells per culture plate was assessed by counting the trypsinized cultures either with the flow microfluorimeter or in a hemocytometer. Duplicate plates were assayed. Cultures were labeled with [3H]thymidine, fixed, and processed for autoradiography by standard methods (2). These techniques, along with flow microfluorimetry (FMF), were used during an experiment to analyze the extent and duration of the synchrony and the rate at which the cells progressed through the cell cycle.

Materials

The established glioma cell line Cs was obtained from the American Type Culture Collection. Fetal calf serum from Flow Laboratories Inc. (Rockville, Md.) and E-glutamine (Grand Island Biological Co. [GIBCO], Grand Island, N. Y.) were used to supplement DMEM from GIBCO. ATP, GTP, and cyclic AMP were purchased from Sigma Chemical Co. (St. Louis, Mo.), [3H]thymidine (30-60 Ci/mmol), [3H]cyclic AMP (40-60 Ci/mmol), [3H]cyclic AMP (40-60 Ci/mmol), and [3H]DHA HCl (40-60 Ci/mmol) were obtained from New England Nuclear (Boston, Mass.). ATP, GTP, cyclic AMP, phosphoryl pyruvate, bovine 3',5'-cyclic nucleotide phosphodiesterase, pyruvate kinase, L-isoproterenol HCl, L-epinephrine, and L-norepinephrine HCl were purchased from Sigma Chemical Co. L-propranolol HCl and other isopropenol HCl came from Ayerst Laboratories (New York), and β-isopropenol-o-biarnate was purchased from Hassel Products, Inc. (Bellport, N. Y.). Norit SG Extra charcoal was purchased from J. T. Baker Chemical Co. (Phillipsburg, N. J.). Whatman GF/C filters were used. Beckman Instruments, Inc. (Fullerton, Calif.) manufactures BioSolv BBS-3, and 2,4-bis [(5-phenylacetyl)amino]methyl}-6-ethyl-2H-pyran-2-ol was the gift of Dr. H. Sheppard, Hoffmann-LaRoche, Inc. (Nutley, N. J.).

RESULTS

Cyclic AMP Levels in Synchronized Cs Cultures

The basal intracellular level of cyclic AMP was measured during the hours before and after mitosis (Fig. 1). The mean cyclic AMP levels of cultures showed a significant and transient decrease at a point coinciding with the peak mitotic index. As the cell population entered G1, the amount of intracellular cyclic AMP invariably increased to levels meeting or exceeding those found before mitosis.

Responsiveness of Intact, Synchronized Cs Cells to β-Adrenergic Stimulation

(–) Isoproterenol (0.1 μM) is capable of rapidly elevating the intracellular level of cyclic AMP in cultured Cs glioma cells (13). This catecholamine stimulation was more pronounced in the presence of the phosphodiesterase inhibitor Ro-20-1724 (15 μg/ml), and was rapidly inhibited upon addition of the β-adrenergic antagonist (–) propranolol (not shown), consistent with the stimulation of adenylate cyclase activity through the β-adrenoceptor. The cyclic AMP accumulation in response to 0.1 μM (–) isoproterenol reached a maximum in ~20 min (~5,000 pmol cyclic AMP/mg protein) of which the initial 3-5 min were linear (data not shown). Because it was desirable to rapidly measure the (–) isoproterenol responsiveness of synchronized Cs cells before adenylate cyclase desensitization (8, 43) or cyclic AMP efflux (29) occurred, such cells were incubated with hormone for only 2 min before the reaction was terminated with TCA. The measured cyclic AMP was therefore an indication of the initial rate or activity of adenylate cyclase rather than of the total capacity of the Cs cells to accumulate cyclic AMP. Control studies using multiple cultures confirmed that the experimental variability of the 2-min incubation period was <10%.

The accumulation of cyclic AMP during a 2-min exposure to 0.1 μM (–) isoproterenol was measured in double thymidine synchronized cells that had subsequently been treated with 0.13 μM colcemid during mid-S phase. Experiments performed to examine the effect of colcemid on cellular hormone response showed that a concentration of colcemid (1 μM) eightfold higher than that used for mitotic arrest (0.13 μM) had no significant effect on the isoproterenol responsiveness of exponentially growing Cs cells. This synchronization technique was employed for the intact cell hormone stimulation studies as well as the subsequent analysis of adenylate cyclase and [3H]DHRA-binding activities. The varying responsiveness of the cells to isoproterenol during the cell cycle is shown in Fig. 2, which is a representative experiment using both high and low density cultures. The mean cyclic AMP accumulation in the higher density cultures remained constant during ~5 h before mitosis (regardless of the presence or absence of colcemid) until a significant decrease in sensitivity occurred at 11 h, the time of maximal accumulation of mitotic cells in this experiment. Isoproterenol responsiveness increased after the cells were released from mitotic arrest and had advanced into the G1 phase of the cell cycle. The low density cultures showed similar changes but exhibited a more dramatic increase as the cells advanced from M to the early G1 phase.

![Figure 1: Basal cyclic AMP levels during the cell cycle. Basal cyclic AMP was extracted from rinsed cultures with 5% TCA. The mean ± SE of cyclic AMP levels is shown on the graph. Cell counts were by the FMF technique. These results are representative of four different synchrony experiments.](https://example.com/figure1.png)
Adenylate cyclase activity was measured at three different time points within the cell cycle: at approximately t = 6 h, 10 h, and 14 h, corresponding to the late S, M, and early G1 phase, respectively. Four different plates of C6 cultures (each yielding separate homogenates) were assayed at each cell cycle time point to measure cyclase activity (Table I). In these experiments, sodium fluoride, GTP, and isoproterenol were capable of stimulating adenylate cyclase to activities 3- to 24-fold above basal enzyme activity. It is evident (Table I) that the stimulated adenylate cyclase enzyme decreased in specific activity as the cells traversed the cell cycle from the latter part of the S phase to mitosis. Moreover, homogenates from G1 phase cells generally had significantly elevated specific activities relative to the activities observed during mitosis. This is consistent with the observations of reduced levels of basal cyclic AMP and the decreased rate of cyclic AMP synthesis during incubation of mitosis-enriched cells with isoproterenol. Although a combination of GTP and isoproterenol increased the enzyme activity observed in the synchronized cells (not shown), it did not
Unsynchronized cultures.

$ P < 0.01 \quad * P < 0.005.

Increased adenylate cyclase activation that can be promoted by (see Table I).

Such ratios calculated from the S or G, phase enzyme activities activity to basal activity in M phase homogenates, relative to was an increased ratio or index of stimulated adenylate cyclase ever, it was generally observed that M phase homogenates were M phase-specific decline in adenylate cyclase activity. How-

GTP and isoproterenol together (Fig. 3) does not reverse the reverse the decline in isoproterenol-stimulated specific activity observed as cells progressed from S to M. Therefore, the increased adenylate cyclase activation that can be promoted by GTP and isoproterenol together (Fig. 3) does not reverse the M phase-specific decline in adenylate cyclase activity. However, it was generally observed that M phase homogenates were more responsive to GTP, NaF, and isoproterenol, i.e., there was an increased ratio or index of stimulated adenylate cyclase activity to basal activity in M phase homogenates, relative to such ratios calculated from the S or G, phase enzyme activities (see Table I).

Cell Cycle Dependence of $[^3H]$DHA Binding to Membrane Preparations

The $\beta$-adrenergic antagonist (—) $[^3H]$DHA was used to characterize the $\beta$-adrenergic receptor as a function of the cell cycle. $[^3H]$DHA bound to membrane preparations from unsynchronized Cs cells in a manner typical of $\beta$-adrenergic stimulation: by use of incubation conditions identical to those used for the adenylate cyclase assay to facilitate comparisons, the binding was observed to be rapid and reversible. Competition for the binding sites was stereospecific by both $\beta$-agonists and $\beta$-antagonists and in the same order of potency as observed for adenylate cyclase activation (see above). Agonist competition was sensitive to GTP as previously reported (19, 20) but not to NaF. The binding was also saturable as examined by measuring the specific binding (see Materials and Methods) of increasing $[^3H]$DHA concentrations to the membrane preparations. The $K_D$ of $[^3H]$DHA binding could then be determined by analyzing these data by the methods of Scatchard (34). Fig. 5 shows the binding isotherm of one such experiment and the linear Scatchard plot generated from these data. The $K_D$ calculated from this experiment was 1.5 nM and the binding capacity of the membranes equaled 0.46 pmol $[^3H]$DHA bound/mg protein. Hill coefficients ranging from 0.9 to 1.2 indicate that Cs cell membrane $\beta$-receptors are neither positively nor negatively cooperative for binding of this tracer ligand.

To determine whether changes in the $\beta$-adrenergic receptor might account for the alterations in isoproterenol-responsive adenylate cyclase activity in S vs. M cells, we measured the $K_D$ and binding capacity of the $\beta$-adrenergic receptor sites in late S, M, and early G, phase cell membrane preparations by saturation binding assays and Scatchard analysis. Table II presents the data from two cell synchrony experiments. There was clearly no change in the receptor $K_D$ for $[^3H]$DHA between synchronized and unsynchronized preparations within those phases of cell cycle that were examined. There was also little difference in the membrane binding capacity for the radiolabeled antagonist in preparations from thymidine-blocked (G, S phase), S phase, or mitotic cells. It is, therefore, doubtful that alterations in the $\beta$-receptor sites are the basis for the decreased enzyme activity (or increase in stimulation index) observed between S and M phase cells. The mean binding capacity did appear to increase in early G, to a quantity roughly equal to that found in unsynchronized (exponentially growing) cultures and may indicate one mechanism by which the adenylate cyclase activity increases upon progression from the M to G, phase. In summary, the only difference in $\beta$-receptor sites that was detected...
in S, M, and G₁ phase cells was a possible increase in the number of specific [³H]DHA-binding sites as cells completed M and entered the G₁ phase.

DISCUSSION

Decreased cyclic AMP levels were found in C₆ cultures enriched for mitotic cells using chemical synchronization methods. The lowest cyclic AMP levels invariably coincided with the peak in MI. At a point after the majority of the cells had completed mitosis, but still early in the G₁ phase, there was a rapid increase in the cellular cyclic AMP content. The present and previous observations (5, 26, 36, 39, 44, 45) that mammalian mitotic cells contain less cyclic AMP per milligram of cell protein than cells in interphase (i.e., the G₁, S, and G₂ phases) indicate the generality of this phenomenon.

We also examined the ability of the β-adrenergic agonist isoproterenol to activate the cyclic AMP synthetic enzyme adenylate cyclase and increase the accumulation of cyclic AMP in whole cells. For these hormone response studies using intact C₆ cells, we chose a 2-min incubation time with isoproterenol because during this short interval the accumulation of cyclic AMP in unsynchronized cultures was linear, reflecting the enzymatic rate of cyclic AMP synthesis. Complications brought on by the secretion of intracellular cyclic AMP in C₆ cells in response to the elevated cyclic AMP levels produced by hormone stimulation could be ignored, as this phenomenon was observed only after longer periods of incubation with hormone (29). Similarly, hormonal desensitization during this period would be negligible (8, 43). The rate of cyclic AMP accumulation in response to isoproterenol stimulation remained relatively constant during the mid to late S phase and early G₂ phase but decreased as cells entered mitosis. After the mitotic phase, as cells entered G₁, the cells exhibited a significantly enhanced responsiveness to isoproterenol. Although hormone responsiveness increases with C₆ cell density, the cell cycle-related changes were density independent. Moreover, in contrast to the previous observation that microtubule-disrupting agents increase the cellular accumulation of cyclic AMP in response to hormones (32), the C₆ cells β-adrenergic hormonal response is not significantly affected by colchicine or colcemid. These data confirm the recent results of Gibb et al. (12). Thus, the lower response of mitotic C₆ cells to isoproterenol appears to reflect a decreased capacity to synthesize cyclic AMP during mitosis.

Changes in hormonal responsiveness have been previously shown to occur during unusual physiological or pathological conditions. For example, responsiveness to a hormone decreases after extended cellular exposure to that hormone, a phenomenon known as hormonal desensitization (25). Super-sensitivity that occurs after an extended period of hormonal deprivation has been associated with an increased density of receptors. Alterations in hormone response that occur upon neoplastic transformation (7, 22, 27, 37) may be related to the receptor changes (38). Other pathological states are known to be caused by changes in hormone receptors and/or hormonal response (9, 11, 15).

We examined the β-adrenergic receptor sites and adenylate cyclase activity in synchronized C₆ cells in an attempt to determine which component(s) of hormone-stimulated adenylate cyclase activity correlates with the decreased cyclic AMP level in the mitotic cell. Such an undertaking, it was hoped, might also indicate the physiologically relevant mechanism(s) by which cells autoregulate their synthesis of cyclic AMP. Direct binding studies using the β-adrenergic radioligand (-)[³H]DHA indicated that no change in β-adrenergic receptor-affinity occurred during the S, M, and early G₁ phases. Receptor density did not differ in S and M phase membranes but increased in early G₁ relative to S and M phase cells, suggesting that β-adrenergic hormone binding sites are maintained at a constant density in the C₆ plasma membrane, just as total cellular protein increases linearly with the cell cycle (31).

The mean specific activity of adenylate cyclase was lower in membrane preparations from mitotic cells than from either S phase or early G₁ phase cells. This was generally true regardless of whether the enzyme activity was assayed in the absence or presence of GTP, fluoride, or isoproterenol (Table I). These changes are consistent with the reduced cyclic AMP levels and the reduced rate of accumulation of cyclic AMP in response to isoproterenol that were observed in whole mitotic C₆ cells. They also confirm earlier reports (14, 26, 28) which indicated that the adenylate cyclase activity of mitotic cells is less than the activity in S or G₁ phase cells, in contrast to one other report (23). The more or less uniform decrease that we observed in the cyclase activity of mitotic cells as well as the subsequent increase in the G₁ enzyme activity are interesting in light of the data (e.g., reference 21, and our Figs. 3 and 4) that each of these adenylate cyclase effector molecules (GTP, NaF, hormone) acts by separate mechanisms to increase the C₆ cell's enzyme activity. Moreover, we found no evidence for an unequal distribution of soluble cytoplasmic substances (e.g., calmodulin) within different phases of the cell cycle (as assayed on sucrose gradient-purified C₆ cell membranes) which could account for the phase-specific changes in cyclase activity.²

A most unexpected observation was that, while both the basal and effector-stimulated adenylate cyclase activities decreased during mitosis relative to the S phase and G₁ phase activity, the adenylate cyclase stimulation index (stimulated cyclase activity/basal activity) increased in mitotic cells relative to the S or G₁ phases. Thus, although the basal activity decreased during mitosis, the three enzyme activators (GTP, NaF, and isoproterenol) increased the basal adenylate cyclase activity more efficiently during this phase of the cell cycle.

This paper further substantiates that the plasma membrane of the mitotic cell is functionally altered (1). Structural changes in the membrane have previously been reported in G₂ (41, 42) and mitosis (10, 18, 30). We also observed a quantitative

² R. F. Howard and J. R. Sheppard. Unpublished observations.
change, but no qualitative changes, in the membrane-associated β-adrenergic receptor as cells completed mitosis and entered the G1 phase. This may be partially responsible for the increased hormone responsiveness of the G1 phase cell.

The molecular mechanisms leading to the decreased absolute cyclase activity and the apparent increase in coupling efficiency of the adenylate cyclase in mitotic C6 cells may involve changes in the G/F (21) or N (6, 17) protein which is required for the stimulation of enzyme activity. This protein and/or the intrinsic catalytic component of the adenylate cyclase membrane complex could be affected by the dynamic physiological changes occurring in the mitotic cell. While the biological importance of this change in membrane function is currently unclear, the decreased basal and stimulated adenylate cyclase specific activities during mitosis could conceivably reflect a relationship between cyclic AMP metabolism and cytoskeletal organization (24, 32, 33, 40).

We thank Karen Larson for typing and Dr. David M. Prescott for reading the manuscript.

This work was supported by grants from the Leukemia Task Force and NIH NS14436.

Received for publication 22 August 1980, and in revised form 23 February 1981.

REFERENCES

1. Berlin, R. D., J. M. Oliver, and R. J. Walter. 1978. Surface functions during mitosis. Cell. 15:227-341.
2. Baxevanis, A. D., and D. Malamud. 1981. Autoradiography. Techniques and Application. Harper and Row, New York.
3. Brown, B. L., J. D. Albano, R. P. Ektna, A. M. Sgherzi, and W. Tampion. 1971. A simple and sensitive saturation assay method for the measurement of adenosine 3',5'-monophosphate. Biochem. J. 121:561-562.
4. Brown, E. T., C. D. Borstrom, and V. E. Groppi. Jr. 1976. Altered cyclic AMP synthesis and degradation by C6 cells following prolonged exposure to tunicamycin. Metab. Pharmacol. 12:32-40.
5. Burger, M. M., B. M. Bobik, B. McL. Breckenridge, and J. R. Sheppard. 1972. Growth control and cyclic alterations of cyclic AMP in the cell cycle. Nat. New Biol. 239:161-166.
6. Cassel, D., and T. Fehlauer. 1976. Mechanism of chola receptor action: covalent modification of the guanyl nucleotide binding protein of the adenylate cyclase system. Proc. Natl. Acad. Sci. U. S. A. 75:2669-2673.
7. DeRobertis, F. R., R. Chayoth, and J. B. Field. 1976. The content and metabolism of cyclic adenosine 3',5'-monophosphate and cyclic guanosine 3',5'-monophosphate in adenocarcinoma of the human colon. J. Clin. Invest. 57:641.
8. deVellis, J., and G. Brooker. 1974. Reversal and catecholamine refractoriness by inhibitors of RNA and protein synthesis. Science (Wash. D. C). 186:1221-1222.
9. Drewetz, M. R., and W. M. Burkh. Jr. 1978. Altered activity of the nucleotide regulatory site in the parathyroid hormone-sensitive adenylate cyclase from the renal cortex of a patient with pseudohypoparathyroidism. J. Clin. Invest. 62:1221-1227.
10. Fox, T. O., J. R. Sheppard, and M. M. Burger. 1971. Cyclic membrane changes in animal cells: transformed cells permanently display a surface architecture detected in normal cells only during mitosis. Proc. Natl. Acad. Sci. U. S. A. 68:244-247.
11. Freely, M. J., E. N. Nelson, G. E. Reich, F. P. Field, and L. D. Nunther. 1975. Reduced β-adrenergic responsiveness in hyperthyroid rats. Am. J. Physiol. 229:916-924.
12. Gibbons, J. C., Y. Hsu, W. L. Terasaki, and G. Brooker. 1980. Calcium and microtubule dependence for increased ornithine decarboxylase activity stimulated by beta-adrenergic agonists, dibutyryl cyclic AMP, or serotonin in a rat astrocyte cell line. Proc. Natl. Acad. Sci. U. S. A. 77:995-999.
13. Gilman, A. G., and M. Niremberg. 1971. Effect of catecholamines on the 3',5'-cyclic AMP concentrations of clonal satellite cells of neurons. Proc. Natl. Acad. Sci. U. S. A. 68:2165-2168.
14. Ho, K. C. Landsby, and C. Bergeron. 1976. Cyclic variations of cellular calcium level and of adenylate cyclase responsiveness during the cell cycle of HeLa cells. J. Cell Biol. 70 (2 Pt. 2):396 (Abstr.).